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Control of pathogenic effector T-cell activities in situ
by PD-L1 expression on respiratory inflammatory
dendritic cells during respiratory syncytial virus
infection
S Yao1, L Jiang1, EK Moser2, LB Jewett3, J Wright2, J Du1, B Zhou1,4, SD Davis3, NL Krupp3, TJ Braciale2
and J Sun1,4
Respiratory syncytial virus (RSV) infection is a leading cause of severe lower respiratory tract illness in young infants,
the elderly and immunocompromised individuals. We demonstrate here that the co-inhibitory molecule programmed
cell death 1 (PD-1) is selectively upregulated on Tcells within the respiratory tract during both murine and human RSV
infection. Importantly, the interaction of PD-1 with its ligand PD-L1 is vital to restrict the pro-inflammatory activities of
lung effector Tcells in situ, thereby inhibiting the development of excessive pulmonary inflammation and injury during
RSV infection. We further identify that PD-L1 expression on lung inflammatory dendritic cells is critical to suppress
inflammatory T-cell activities, and an interferon–STAT1–IRF1 axis is responsible for increased PD-L1 expression on lung
inflammatory dendritic cells. Our findings suggest a potentially critical role of PD-L1 andPD-1 interactions in the lung for
controlling host inflammatory responses and disease progression in clinical RSV infection.
INTRODUCTION
Respiratory syncytial virus (RSV) is the most frequent cause of
serious lower respiratory tract illness in infants and young
children worldwide.1 In addition, RSV also leads to significant
morbidity in elderly individuals and those with pre-existing
conditions including chronic lung diseases and congenital heart
diseases.2 Currently there is no approved RSV vaccine or
efficacious treatment available for severe RSV-associated
diseases, except a costly prophylactic antibody licensed only
to high-risk infants. Emerging evidence from experimental
models of RSV infection as well as clinical studies strongly
suggest that the magnitude and features of the host inflam-
matory responses are important to lung injury and overall
disease severity.3–7 Indeed, no firm correlation between disease
severity and the levels of RSV replication was observed,8
suggesting that host inflammation may have a key role in
determining host disease progression during RSV infection. As
such, severe RSV-induced pulmonary disease is typically
accompanied with an exaggerated inflammatory response in
the lower respiratory tract, characterized by the overproduction
of pro-inflammatory cytokines/chemokines and increased
infiltration of inflammatory cells.4,7,9 Hence, control of pulmo-
nary inflammation and the suppression of excess tissue injury
might represent a novel approach to limit the pathology from
RSV infection.
The exactmechanisms underlying the development of severe
pulmonary inflammation and diseases following RSV infection
are not fully understood. Since severe pulmonary inflammation
is only observed in a small fraction of patients, it is estimated
that variation (polymorphisms) among host factors regulating
inflammation may be critical in determining the severity
of inflammation and disease outcome.7,9 Notably, the host
immune and inflammatory responses are tightly regulated by
various immune-regulatory factors including specialized cell
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types (e.g. Foxp3þ regulatory T cells (Treg)) and immune-
regulatory cytokines (e.g. IL-10)). Studies in the murine model
of RSV infection have revealed that Treg cells have a critical role
in limiting severe inflammation and immunopathology during
infection.10–13 Similarly, effector T-cell derived IL-10 has also
been demonstrated to counter-balance host inflammatory
responses and suppress severe pulmonary injury.14–16 Inter-
estingly, allelic polymorphisms in the IL-10 locus are correlated
with the risk of the development of severe bronchiolitis in RSV-
infected children.17,18 Together these data suggest the possi-
bility of preventing the development of excessive lung injury
during RSV infection through the selective engagement and/or
manipulation of immune-regulatory pathways.
Programmed cell death 1 (PD-1) protein is a T-cell co-
inhibitory receptor that belongs to the CD28 family. Unlike the
interaction of CD28 and its ligands, B7 molecules, the
interaction of PD-1 with its ligands, PD-L1 and PD-L2,
delivers potent inhibitory signals to activated T cells. Hence, the
interaction between PD-1 and its corresponding ligands is
important for maintaining tissue homeostasis and preventing
the development of autoimmune diseases.19 Conversely, the
PD-1 pathway has also been shown to allow pathogen
persistence during chronic viral infections by suppressing
the efficient development of T-cell responses.20–22 The roles of
PD-1 and its ligands in acute virus infection are less clear.23
Recently, it was demonstrated that the blockade of PD-1 and
PD-L1 interaction in vivo resulted in elevated host effector
T-cell responses and enhanced viral clearance during influenza
and human metapneumovirus (HMPV) infection, suggesting
that PD-1 and PD-L1may also play a role in restricting effective
anti-viral T-cell responses during acute viral infections.24–26
Similarly, in an in vitro co-culture model, the PD-L1/PD-1
interaction has been shown to inhibit CD8þ T cell effector
function when encountering RSV-infected human epithelial
cells.27 However, the exact function of PD-1 and its ligands
in vivo during RSV infection, particularly within the respiratory
tract, is currently unknown.
We have investigated the role of PD-1 and PD-1 ligand
interaction in regulating RSV pathogenesis and host immune
responses in the lung during experimental RSV infection. We
found that T cells from RSV-infected murine lungs, in
particular IL-10-expressing effector T cells, expressed high
levels of PD-1 compared with their counterparts in the
secondary lymphoid organs. Interestingly, human T cells
isolated from the respiratory tract of RSV-infected subjects also
expressed higher levels of PD-1 than circulating T cells. In the
murine model, blockade of the PD-1 and PD-L1 interaction
in vivo, at the time of T-cell infiltration into the lung, resulted in
enhanced pulmonary inflammation and lung injury but had
only a modest effect on viral clearance. We found that PD-1/
PD-L1 blockade enhanced the pro-inflammatory activity of
effector T cells independent of the action of IL-10 and Treg
cells. We demonstrated that lung inflammatory dendritic cells
(DCs) are themain cellular sources of PD-L1 responsible for the
inhibition of effector T-cell activities. Furthermore, a signaling
pathway involving type I and II interferons (IFNs)–STAT1–
IRF1 was critical for the upregulation of PD-L1 on inflam-
matory DCs. Our analysis has revealed a critical role of IFN-
dependent PD-L1 expression on lung inflammatory DCs in
restricting excessive pulmonary inflammation and injury
during RSV infection.
RESULTS
PD-1 expression on respiratory T cells during murine and
human RSV infection
To define the role of PD-1 in regulating T-cell function in the
lungs during RSV infection, we first examined the kinetics of
PD-1 expression on lung CD4þ and CD8þ T cells following
RSV infection of mice. We found that percentages of PD-1-
expressing cells among lung CD4þ and CD8þ T cells, and
PD-1 expression (mean fluorescence intensity) per cell were
markedly increased at days 5 and 7 post RSV infection, the
time when RSV-specific T cells begin infiltrating to the lungs
(Figure 1a,b and Supplementary Figure S1A online).
Compared with lung T cells, we detected only very modest
PD-1 expression on activated T cells from drainingmediastinal
lymph nodes (MLN, Figure 1c), suggesting that PD-1
expression is primarily restricted to T cells at the site of
infection. We recently demonstrated that effector CD4þ and
CD8þ T cells in the infected lungs express the regulatory
cytokine IL-10 during RSV infection.16 Interestingly, we found
higher PD-1 expression on IL-10 producing lung effector
CD4þ and CD8þ T cells than on activated IL-10 non-
producing lung CD4þ and CD8þ T cells (Figure 1d).
In conjunction with this analysis, we examined whether PD-
1 is expressed on pulmonary T cells following human RSV
infection.We compared the expression of PD-1 on T cells from
peripheral blood and nasal washes of children with RSV
infection (n¼ 6) and from peripheral blood of uninfected
healthy children (n¼ 4). We found that PD-1 expression was
significantly upregulated on CD8þ T cells from the nasal
washes of RSV-infected patients compared with CD8þ T cells
from the subjects’ peripheral blood (Figure 1e,f). We also
examined PD-1 expression on CD4þ T cells and observed a
trend toward PD-1 upregulation on CD4þ T cells in the nasal
washes, which did not reach statistical significance possibly
due to a limited sample size (Supplementary Figure S1B).
Nevertheless, these data suggest that human airway T cells, in
particular CD8þ T cells, express PD-1 during RSV infection.
PD-L1 blockade exacerbated pulmonary inflammation and
host diseases during RSV infection
We next sought to determine the function of PD-1 on lung
T cells during RSV infection. We blocked the interaction of
PD-1 with its ligands PD-L1 or PD-L2 by injection of a-PD-L1
(clone: 10B5) or a-PD-L2 (clone: Ty25) mAb at the time of
T-cell infiltration to the lungs (i.e. day 4 and 6 post infection).
We chose these time points to specifically block PD-1 and PD-
L1 interaction in the lung, rather than to inhibit initial PD-1 and
PD-L1 interaction during T-cell priming in the mediastinal
lymph nodes at the early days following infection (i.e. days 1–4
post infection) since T-cell activation during priming can
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transiently upregulate PD-1.19,28 We found that injection of
blocking PD-L1 Ab significantly enhanced host weight loss
during RSV infection (Figure 2a), suggesting that the PD-L1/
PD-1 interaction is vital for restricting host morbidity. In
contrast, we observed only moderate enhancement of host
morbidity following PD-L2 blockade (Supplementary Figure
S2A), presumably due to the lower levels of PD-L2 expression
in the lung compared with the expression of PD-L1 (Supple-
mentary Figure S2B). These data indicated that PD-L1/PD-1
interaction, but not PD-L2/PD-1 interaction, is critical to
suppress the development of severe host disease during RSV
infection. In parallel, we examined viral replication by
determining RSV-L gene expression in the lung and RSV
titers in the airway following either Rat immunoglobulin-G
(IgG) or a-PD-L1 treatment. We found that both viral genome
content in the lungs (Figure 2b) and virus titers in the airway
(Figure 2c) of mice treated with a-PD-L1 were comparable to
those of control mice, suggesting that enhanced host morbidity
following PD-L1 blockade is not due to enhanced viral
replication in the lung.
We next sought to determine the extent of lung inflamma-
tion/injury following PD-L1 blockade during RSV infection. To
this end, we examined vascular leakage into the lung airway by
Evans-Blue assay.29 We found that mice exhibited significantly
enhanced Evans-Blue extravasation to the airways following
a-PD-L1 treatment (Figure 2d), suggesting that these mice had
enhanced vascular and airway permeability and injury.
Enhanced non-neutralizing RSV-specific Ab production has
been linked to lung damage in secondary RSV infection
following immunization of formalin-inactivated virus, most
probably due to the insufficient T-cell help.30,31 However, mice
received a-PD-L1 exhibited moderately enhanced follicular
T-helper cell (Tfh, a specialized T-helper cell type responsible
for helping B cells32) generation, comparable germinal center B
cell formation and similar serum, and/or airway RSV-specific
IgG levels to mice received control Ab during primary RSV
Figure 1 Murine and human T cells express programmed cell death 1 (PD-1) within the respiratory tract during respiratory syncytial virus (RSV)
infection. (a–c) Wild-type Balb/c mice were infected with RSV. PD-1 expression (a) and % of PD-1þ cells in CD4þ and CD8þ T cells (b) at different days
post infection are depicted. (c) PD-1 expression on activated CD4þ and CD8þ T cells (CD44hi) of lung and mediastinal lymph nodes at day 5 post RSV
infection. (d) IL-10-eGFP reporter (Vert-X) mice were infected with RSV. Mean fluorescence intensity (MFI) of PD-1 expression on naı¨ve, IL-10 , or IL-
10þ (CD44hi) lung T cells is depicted (day 5 post infection). (e, f) Peripheral blood mononuclear cells and nasal washes were collected on healthy children
or RSV-infected children. (e) PD-1 expression on CD8þ T cells is depicted. (f) % of PD-1þ cells in CD8þ T cells is depicted. (a–d) Data are representative
of two to three independent experiments. (e, f) Data are from four healthy and six RSV-infected donors. *, Po0.05 as determined by nonparametric
Mann–Whitney test.
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infection (Supplementary Figure S3), indicating that the
development of enhanced lung damage is unlikely due to the
enhanced deposition of RSV-specific IgG. We also examined
lung injury by lung morphology in hematoxylin and eosin
staining of lung sections from RSV-infected mice. We found
that lungs from a-PD-L1-treated mice demonstrated increased
infiltration of inflammatory cells to the interstitium and
augmented airway wall thickness (Figure 2e). In addition, we
surveyed mice at day 9 post infection for the expression of a
panel of inflammatory mediators in the broncho–alveolar
lavage fluid (BALF) following treatment with a-PD-L1 or
control antibody. We found that a number of these mediators
were elevated in the airway of a-PD-L1-treated mice compared
with those of mice that received control Ab (Figure 2f).
Consistent with increased cytokine and chemokine levels in the
respiratory tract, we observed increased numbers of inflam-
matory cells including neturophils, eosinophils and T cells
in the lungs following PD-L1 blockade (Supplementary
Figure S4A). Taken together, these data demonstrated that
PD-L1/PD-1 interaction in the lung is vital to suppress the
development of excess pulmonary damage and to promote
efficient resolution of pulmonary inflammation.
Figure 2 Programmed cell death 1 (PD-1) blockade following respiratory syncytial virus (RSV) infection leads to enhanced host morbidity and
pulmonary injury. Wild-type Balb/c mice were infected with RSV and treated with control antibody, phosphate-buffered saline (PBS) or a-PD-L1 as
indicated. (a) Host morbidity was monitored through weight loss. (b) RSV replication in the lung was monitored through RSV-L gene expression at
indicated days post infection. (c) Airway virus titers from indicated mice were determined by plaque assay. Day 3, airway RSV titers from day 3-infected
mice; day 6 control, airway RSV titers from day 6-infected mice treated with Rat IgG; day 6 a-PD-L1, airway RSV titers from day 6-infected mice treated
with a-PD-L1. (d) Lung vascular and airway leakage was monitored through Evans-Blue concentrations in the airway at day 7 post infection. (e) Lung
histopathology was measured by hematoxylin and eosin staining at day 7 post infection. (f) Pro-inflammatory cytokine levels in BAL from control or a-PD-
L1-treated mice (day 9 post infection). Data are pooled from two to three experiments (a,c), representative from two to three experiments, (b,d, e) or from
one experiment with four to five mice each group (f). *, Po0.05 was determined by unpaired Student’s t-test (a, d, f), NS, non-significant.
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We and others have recently showed that IL-10 and Foxp3þ
Treg cells played important roles in counter-regulating
excessive pulmonary inflammation and dampening host
diseases during RSV infection.10–16 We reasoned that PD-
L1 blockade might diminish Treg cell infiltration to the lung
and/or impair IL-10 production in the airway, thereby leading
to enhanced host inflammation and injury during RSV
infection. However, PD-L1 blockade resulted in comparable
Treg cell infiltration to the lung (Supplementary Figure S4B)
and enhanced IL-10 release in the airway during RSV infection
(Supplementary Figure S4C). Together, these data suggest that
PD-L1 suppresses host diseases independent of the action of
Treg and IL-10.
PD-1/PD-L1 interaction controls the inflammatory activities
of effector T cells
We next sought to define the underlying mechanism by which
the PD-1 and PD-L1 interaction regulates pulmonary inflam-
mation and injury during RSV infection. As overproduction of
inflammatory cytokine by pulmonary effector T cells con-
tributes significantly to the pulmonary inflammation and host
diseases during primary RSV infection, we examined whether
PD-L1 affects the in vivo production of inflammatory cytokines
by effector T cells during RSV infection. To do so, we injected
monensin into RSV-infectedmice to block the in vivo release of
cytokines by effector T cells at day 5 post infection, when the
peak of inflammatory activities of effector T cells was
observed.16 We then stained (intracellular staining (ICS)) lung
T cells for intracellular IFN-g and tumor-necrosis factor-a
(TNF-a) expression directly ex vivo without further stimula-
tion. This in vivo ICS technique allowed us to precisely
determine the in vivo production of inflammatory cytokines by
effector CD4þ and CD8þ T cells (Figure 3a). We found that
lung effector T cells isolated from a-PD-L1-treated mice
displayed a significantly enhanced frequency of both IFN-g and
TNF-a producing CD4þ and CD8þ T cells compared with
those of control mice (Figure 3a,b). The increased frequency of
IFN-g- and TNF-a-producing cells in vivo following PD-L1
blockade could be caused by increased effector activities of
effector T cells or enhanced infiltration and differentiation of
RSV-specific T cells into the Th1 or Tc1 lineage. To explore
these possibilities, we stimulated the lung effector T cells in vitro
with phorbol 12-myristate 13-acetate (PMA) and ionomycin
and examined the capabilities of lung effector T cells to produce
IFN-g and TNF-a following mitogenic stimulation. We found
that effector T cells from either control or a-PD-L1-treated
mice had comparable capability to produce IFN-g and TNF-a
in response to mitogenic stimulation (Figure 3c,d), suggesting
that PD-L1 blockade at day 4 post infection does not affect the
differentiation of T cells into RSV-specific effector T cells to the
Th1 or Tc1 lineage.
To provide direct evidence that PD-L1 controls the pro-
inflammatory responsiveness of pulmonary effector T cells
during RSV infection, we established an in vitro culture system.
Effector CD8þ T cells were isolated from RSV-infected lungs
8 days post infection (d.p.i.; when spontaneous production of
cytokines by effector T cells due to in vivo antigen (Ag)
encounter is minimal16), and stimulated in vitro with a low
concentration of plate-bound a-CD3 to mimic in vivo Ag
encounter. PD-1 expressed on effector T cells was simulta-
neously ligated by addition of recombinant PD-L1–Ig fusion
protein to the cultures. We found that IFN-g release by effector
T cells was drastically decreased following the ligation of PD-1
(Figure 3e), suggesting that PD-1 ligation on effector T cells
directly suppresses the release of IFN-g by effector T cells.
Taken together, these data suggested that PD-L1/PD-1 interac-
tion in the lung suppress the inflammatory activities (release of
inflammatory cytokines) of effector T cells in vivo but not
affecting the induction, accumulation or differentiation of
lung effector T cells at this early time point (though it is the peak
of in vivo effector T-cell activities) following RSV infection.
Consistent with enhanced IL-10 production in the airway, we
also found that PD-L1 blockade enhanced IL-10 production
by effector CD4þ and CD8þ T cells (Supplementary
Figure S4D,E), again suggesting that the effects of PD-L1
blockade is not due to decreased IL-10 production in vivo
during RSV infection.
PD-L1 expression on inflammatory DCs regulates
inflammatory activities of effector T cells
PD-L1 is constitutively expressed on various lung cell types and
can be further upregulated during infection or inflammation.
We next measured PD-L1 expression in the lungs before or
during RSV infection. We found that PD-L1 levels in the lung
dramatically increased following RSV infection (Figure 4a).
Both hematopoietic and non-hematopoietic cells demonstrated
increased PD-L1 expression and exhibited the same kinetics as
observed in total lung cell suspensions (data not shown).
Todetermine themajor cellular resources ofPD-L1 at the timeof
T-cell infiltration, we examined surface PD-L1 expression by
various lung residents and infiltrating cells at day 5 post RSV
infection.We found that, although various types of cells in the lung
appear to express PD-L1 (Figure 4b), lung inflammatory
monocyte-derived DCs (CD11bþCD11cþLy6CþMHCIIþ ,33,34
Supplementary Figure S5A,B) and lung resident cells such as
CD45 cells (primarily lung epithelial cells) are the two major
cellular sources of PD-L1 in the lung during RSV infection
(Figure 4c) following adjustment for their levels of PD-L1
expression and relative cellular abundance in the lung
(Supplementary Figure S5C). However, inflammatory DCs
appear to be the dominant cellular source of PD-L1 (Figure 4c).
We also found that inflammatory DC cell numbers in the lung
increased drastically following RSV infection (Supplementary
Figure S5D), and PD-L1 expression on inflammatory DCs
increased similarly to expression in total lung cells following
RSV infection (Supplementary Figure S5E).
During acute influenza infection, inflammatory DCs, but not
lung resident cells, have been reported to predominantly
stimulate inflammatory cytokine release by effector T cells in
the lungs.35 We therefore hypothesized that PD-L1 expressed
by inflammatory DCs, rather than by CD45 lung resident
cells, serves to control excessive inflammatory activities of
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effector T cells during RSV infection. To test this idea, we co-
cultured either inflammatory DCs or lung resident cells with
CD8þ effector T cells isolated from RSV-infected lungs, and
measured production of IFN-g in supernatant in the absence or
presence of a-PD-L1. Consistent with findings in the influenza
infection,35 we found that only minimal amount of IFN-g was
produced in the lung resident cell-T co-culture, while copious
amount of IFN-g was detected in inflammatory DC-T co-
culture (Figure 4d), indicating that inflammatory DCs, rather
than the lung resident cells, are the primary Ag presenting cells
in vivo to stimulate cytokine production by effector T cells
during RSV infection. Strikingly, blockade of the PD-L1/PD-1
interaction between inflammatory DCs and effector CD8þ T
cells resulted in greatly enhanced IFN-g production by effector
CD8þ T cells (Figure 4d). Thus, our data indicated that PD-L1
expressed by inflammatory DCs controls inflammatory
activities of effector T cells in the lung in vivo during RSV
infection.
An IFN–STAT1–IRF1 axis is critical to induce PD-L1
expression on inflammatory DC during RSV infection
We next sought to determine the molecular mechanism by
which PD-L1 is induced on inflammatory DCs during RSV
infection. The induction of PD-L1 on inflammatory DCs
during RSV infection is independent of IL-10 since IL-10R
blockade did not affect PD-L1 expression on inflammatoryDCs
(Supplementary Figure S5F). IFNs, in particular IFN-g, are
capable of inducing PD-L1 expression on DCs and
macrophages in vitro and in vivo.36,37 We next examined
whether STAT1, the IFN-downstream signaling molecule,38 is
required for the expression of PD-L1 on inflammatory DCs
during RSV infection. Since STAT1 is an important innate anti-
viral molecule, to avoid potential additional complexity due to
the effects of STAT1 deficiency on epithelial anti-viral
responses, we generated a wild-type (WT) and STAT1-
deficient mixed bone marrow (BM) chimera. To do so, we
lethally irradiated WT mice and then reconstituted the mice
with mixed WT and STAT1-deficient BM cells (1:1 ratio).
Twelve weeks after reconstitution, we generated chimeric mice
that have WT epithelial cells with 1:1 mixed WT or STAT1-
deficient hematopoietic cells (Figure 5a). We then infected the
mice with RSV and examined PD-L1 expression on lung
inflammatory DCs at day 5 post infection. We found that
STAT1 deficiency drastically diminished PD-L1 levels on
inflammatory DCs (Figure 5b), suggesting that intrinsic
STAT1 signaling in inflammatory DCs is required for the
Figure 3 PD-L1 blockade results in enhanced inflammatory activities of effector T cells. (a–d) Wild-type Balb/c mice were infected with respiratory
syncytial virus (RSV) and treated with phosphate-buffered saline (PBS) or a-PD-L1. At day 5 post infection, mice were injected with monensin to block the
in vivo secretion of cytokines by T cells. (A) Direct interferon-g (IFN-g) and tumor-necrosis factor-a (TNF-a) staining of ex vivo lung CD4þ and CD8þ T
cells without in vitro stimulation. (b) % of IFN-gþ and TNF-aþ cells in ex vivo lung CD4þ and CD8þ T cells without in vitro stimulation. (c, d) Lung CD4þ
and CD8þ T cells were stimulated with phorbol 12-myristate 13-acetate (PMA) and Ionomycin (c). IFN-g and TNF-a production by T cells are depicted.
(d) % of IFN-gþ and TNF-aþ cells in lung CD4þ and CD8þ T cells following PMA and Ionomycin stimulation. (e) Effector CD8þ T cells were isolated from
RSV-infected lungs (day 8) and stimulated in vitro with increasing amount of plate-bound a-CD3 (0.01 and 0.1 mg ml1) in the absence or presence of
recombinant PD-L1–Ig protein. IFN-g concentrations in the supernatant following 24 h stimulation are depicted. Data are representative of three
independent experiments. *, Po0.05 as determined by unpaired Student’s t-test.
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expression of PD-L1. We next examined whether type I IFNs
(IFN-a/b) or II IFN (IFN-g) is required for the induction of PD-
L1 on inflammatory DCs. We found that inflammatory DCs
from IFNAR1-deficient mice or from mice in which IFN-g has
been neutralized exhibited slightly diminished PD-L1 expres-
sion, demonstrating that type I or II IFN-deficiency alone only
moderately decreased PD-L1 expression (Figure 5c,d).
Strikingly, the co-blockade of type I and II IFNs drama-
tically inhibited the expression of PD-L1 on inflammatory DCs
(Figure 5e). The blockade of type I and II IFNs together also
diminished PD-L1 messenger RNA in inflammatory DCs
(Figure 5f). Taken together, these data suggested that PD-L1
expression on inflammatory DCs in vivo during RSV infection
requires the co-ordination of type I and II IFN signaling
through STAT1. Consistent with this idea, we found that type I
and II IFNs co-operated to enhance PD-L1 expression on
BM-derived DCs (BMDCs) in vitro (Figure 5g).
We next investigated transcription factors downstream of
IFN/STAT1 that are required for the expression of PD-L1 on
inflammatoryDCs. To this end, we found that both type I and II
IFNs enhanced expression of the transcription factor IRF1 in a
manner dependent on STAT1 (Figure 6a). IRF1 expressionwas
previously shown to be required for PD-L1 expression on
human cancer cell lines in vitro.39 However, the role of IRF1 in
regulating PD-L1 expression in other cell types, especially in the
in vivo setting was not previously investigated. We therefore
investigated the role of IRF1 in regulating PD-L1 expression on
inflammatory DCs. Consistent with our in vitro data, we found
the absence of type I and II IFNs and IFN receptor signaling
in vivo diminished IRF1 expression in inflammatory DCs
(Supplementary Figure S6). To examine the role of IRF1 in
regulating PD-L1 expression on inflammatory DCs in vivo, we
infected IRF1-deficient mice with RSV and examined PD-L1
expression on lung inflammatory DCs at day 5 post infection.
We found that IRF1 deficiency significantly impaired PD-L1
expression on lung inflammatory DCs in vivo (Figure 6b,c).
IRF1 is also an important anti-viral molecule and IRF1 is
required for CD8þ T-cell development.40 To avoid these
Figure 4 Inflammatory dendritic cell (DC)-derived PD-L1 inhibits cytokine production by effector T cells. (a–c) Wild-type Balb/c mice were infected with
respiratory syncytial virus (RSV). (a) PD-L1 expression (mean fluorescence intensity (MFI)) in the lung cells. (b) PD-L1 expression on various cell types in
the lung (day 5 post infection). AM, alveolar macrophages; CD45 , CD45 lung resident cells; iDC, Inflammatory DCs; MC, Ly6GCD11bþCD11c
monocytes; Neu, neutrophils. (c) Relative expression levels of PD-L1 on different cell types (PD-L1 relative expression was calculated by PD-L1 MFI%
of cells in the lungs). (d) iDC and CD45 resident cells were sorted from the infected lungs at day 5 post infection. Cells were then mixed with day 8 lung
CD8þ effector T cells in the presence of control Ab or a-PD-L1. Interferon-g concentrations in the supernatant following 24 h stimulation are depicted.
Data are representative of two to three independent experiments.
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potential caveats, we generated mixed bone marrow chimera
(Figure 6d) as described above (Figure 5). We found that
IRF1-deficient inflammatory DCs exhibited impaired PD-L1
expression compared with their WT counterparts under
the same environment (Figure 6e). These data collectively
demonstrated that intrinsic expression of IRF1 by inflamma-
tory DCs is required for the expression of PD-L1 on inflam-
matory DCs in vivo during RSV infection. To examine whether
IRF1 expression is sufficient to promote PD-L1 expression on
DCs, we transduced BMDCs with control or IRF1-expressing
retroviruses and examined PD-L1 expression on transduced
DCs. We found that ectopic IRF1 expression enhanced PD-L1
expression on BMDCs (Figure 6f,g), suggesting that IRF1 is
sufficient to induce PD-L1 expression on DCs. Since IRF1 was
required for PD-L1 expression and PD-L1 expression on
inflammatory DCs controlled inflammatory activities of
effector T cells, we reasoned that IRF1 deficiency in inflam-
matory DCs would augment cytokine production by effector T
cells upon Ag encounter. To test this hypothesis, we infected
WT or IRF1-deficient mice with RSV, isolated WT or IRF1-
deficient inflammatory DCs and then mixed them with WT
effector T cells from RSV-infected lungs. We found that IRF1
deficiency in inflammatory DCs, (but not in CD45 epithelial
cells), greatly augmented IFN-g production by effector T cells
(Figure 6h). Taken together, these data suggested that an
IFN–STAT1–IRF1 axis is required for the expression of PD-L1
on inflammatory DCs and the control of inflammatory
activities of effector T cells during RSV infection.
DISCUSSION
In this report, we have examined the expression and function of
PD-1 and PD-L1, specifically in the lung, during RSV infection.
We found that PD-1 and PD-L1 interactions minimally
affected RSV viral clearance but drastically modulated the
development of excessive pulmonary inflammation and lung
injury during RSV infection.We found that engagement of PD-
1 by inflammatory DC-derived PD-L1 is critical for the
regulation of pro-inflammatory cytokine release by effector
CD4þ and CD8þ T cells, and as a result, the control of the
inflammatory effector T-cell activities in vivo in the lung. In
addition, we have identified the physiological cues and
underlying signaling pathways responsible for PD-L1 expres-
sion on inflammatory DCs during RSV infection. We found
that an IFN–STAT1–IRF1 axis is critical for the upregulation of
Figure 5 Type I and II interferon (IFNs) co-operatively induce PD-L1 expression on inflammatory dendritic cells (DCs) during respiratory syncytial virus
(RSV) infection. (a, b) Wild-type (WT):Stat1 / mixed bone marrow (BM) chimeric mice were infected with RSV. (a) Schematics of BM chimera
construction and RSV infection. (b) PD-L1 expression (mean fluorescence intensity (MFI)) on WT and STAT1-deficient lung inflammatory DCs (iDC) in
the same host at day 5 post infection. (c) WT and IFNAR1-deficient mice were infected with RSV. PD-L1 expression on WT and IFNAR1-deficient lung
iDCs at day 5 post infection. (d) WT mice were infected with RSV and treated with control Ab or neutralizing a-IFN-g. PD-L1 expression on lung iDCs at day
5 post infection. (e, f) WT and IFNAR1-deficient mice were infected with RSV and treated with a-IFN-g as indicated. PD-L1 MFI (e) and messenger RNA
message (f) on lung iDCs at day 5 post infection. (g) Bone marrow-derived DCs (BMDCs) were treated with phosphate-buffered saline, IFN-a, IFN-g, or
IFN-aplus IFN-g. PD-L1 MFI on BMDCs is depicted. Data are representative of two to three independent experiments. *,Po0.05 as determined by paired
Student’s t-test (b) or one way analysis of variance and Bonferroni post test (e).
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PD-L1 on inflammatory DCs and as a consequence, suppres-
sion of the release of cytokine production by effector T cells.
We found that PD-1 is highly expressed on both human and
mouse T cells at the respiratory tract during RSV infection.
Currently, due to the extreme low numbers of cells we
recovered from the nasal washes of healthy children, we were
unable to determine whether PD-1 is expressed on human CD4
and/or CD8 T cells residing in the respiratory tract of healthy
children. However, we found that PD-1 is minimally expressed
on T cells in the respiratory tract in uninfectedmice, suggesting
that local inflammation and/or Ag encounter at the respiratory
tract trigger the upregulation of PD-1 on T cells during RSV
infection. These data are in line with recent reports of PD-1
expression on lung T cells during influenza and HMPV
infection.24–26 Interestingly, we further found that PD-1 is
highly upregulated on IL-10 producing effector T cells,
suggesting that IL-10 and PD-1 expression in T cells may
be regulated by the same molecular machinery during RSV
infection. Notably, we recently showed that the transcription
factor Blimp-1 promoted IL-10 production by effector T cells
during influenza infection. Furthermore, Blimp-1 modulates
PD-1 expression during chronic virus infection.41 Thus, Blimp-
1 may promote the upregulation of PD-1 on effector T cells in
the respiratory tract, although further studies are warranted.
We also detected significant expression of inhibitory molecules
such as Lag-3 and Tim-3 on IL-10 producing effector T cells
(data not shown), suggesting that certain lung effector T cells
simultaneously express multiple inhibitory molecules along
with the regulatory cytokine IL-10. We believe that such a
regulatory constellation may reflect the process of lung effector
T cells adapting to the local inflammatory environment to
restrict excess production of inflammatory mediators that
enhance lung injury. Interestingly, it was shown recently that
PD-1-expressing exhausted T cells undergo a form of
Figure 6 IRF1 is required for PD-L1 expression on inflammatory DCs (iDC) during respiratory syncytial virus (RSV) infection. (a) IRF1 expression
in wild-type (WT) or STAT1-deficient bone marrow-derived DCs (BMDCs) treated with phosphate-buffered saline (PBS), interferon-a (IFN-a) or IFN-g.
(b, c) PD-L1 expression (b) and mean fluorescence intensity (MFI) (c) on iDCs isolated from lungs of RSV-infected WT or IRF1-deficient mice (day 5 post
infection). (d, e) WT: Irf1 / mixed BM chimeric mice were infected with RSV. (d) Schematics of BM chimera construction and RSV infection. (e) PD-L1
expression (MFI) on WT and IRF1-deficient lung iDCs in the same host at day 5 post infection. (f, g) BMDCs were transduced with control or IRF1-
expressing retroviruses. PD-L1 expression (f) and MFI (g) on control virus or IRF1-expressing-virus transduced DCs are depicted. (h) WT or IRF1-
deficient lung iDCs was sorted from infected WT or Irf1 / mice, respectively, at day 5 post infection. Cells were then mixed with day 8 lung CD8þ effector
T cells in the presence of control Ab or a-PD-L1. IFN-g concentrations in the supernatant following 24 h stimulation are depicted. Data are representative
of three independent experiments. *, Po0.05 as determined by unpaired (c, g) or paired Student’s t-test (e).
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differentiation that can be stably transmitted to daughter cells
during chronic lymphocytic choriomeningitis virus infection.42
It is thus enticing to speculate that these PD-1-expressing
effector T cells at sites of infection/inflammation may also
pass through a stable and transmissible differentiation state.
Furthermore, we observed that PD-1 expression on human
airway T cells was quite variable among different individuals.
Given the limited numbers of human samples in our study, we
were unable to correlate PD-1 expression on airway T cells with
the severity of host diseases. Future large-scale studies are
warranted for the determination of whether PD-1 expression
levels and/or polymorphisms in PD-1 locus are associated with
the severity of RSV-induced diseases in children. Of note, a
polymorphism in the locus of IL-10, another important
immune-regulatory factors in restricting host inflammatory
responses during murine RSV infection,14–16 was shown to be
associated with the severity of bronchiolitis in infants infected
with RSV.17,18,43
PD-1 interacts with both PD-L1 and PD-L2.19We found that
the blockade of PD-L1 but not PD-L2 greatly enhanced host
morbidity and lung inflammation/injury during RSV infection.
The different expression levels of PD-L1 and PD-L2 in the lung
following RSV infectionmay explain the differential function of
PD-L1 and PD-L2 on host disease development. Notably, PD-
L2 expression is primarily controlled by type 2 cytokines such as
IL-4 and IL-13.44 Unlike RSV A2 strains used in this study,
certain RSV strains, including line19 and 2-20, were shown to
selectively induce Th2 cytokine production and asthma-like
symptoms including mucus production and airway resis-
tance.45,46 Therefore, it is possible that PD-L1 and PD-L2
blockade may have different functional consequences during
the infections by different RSV strains. Of note, the blockade of
PD-L2 was reported to selectively enhance Th2 cytokine
production and asthmatic symptoms in a murine model of
asthma.44
The treatment with blocking anti-PD-L1 antibody during
HMPV and influenza infections has been demonstrated to
greatly enhance CD8þ T cell numbers and in the case of
influenza facilitate viral clearance.24–26 However, only modest
effects on host morbidity and lung injury were noted.24–26 In
contrast, we showed here that the PD-L1 blockade only
modestly affected the early anti-RSV T cell response and viral
clearance but drastically promoted host weight loss and tissue
injury. Such dichotomy may be attributed to the inherent
differences in virus replication, tissue tropism, and the immune
response stimulated between RSV, HMPV, and influenza.
During the infection with viruses that replicate to high levels
such as influenza and HMPV infection, the beneficial effect of
PD-L1 in restricting exuberant T-cell-mediated inflammation
is probably compensated by enhanced virus induced injury
caused by the reduction of T cell anti-viral activity. Further-
more, previous studies blocked PD-L1 activity prior to
infection.24–26 Since PD-1 can be transiently upregulated
during T cell priming,19,28 it is possible PD-L1 blockade
may enhance T-cell activation and proliferation during T cell
priming within the draining lymph nodes, thereby promoting
effector T cell accumulation and function at the site of
infection. In contrast, we chose to block PD-L1 and PD-1
interaction at the time of T cell infiltration to the lung to
specifically determine the function of PD-L1 and PD-1
interaction in the lung in regulating tissue inflammation
and viral clearance during RSV infection. Our results showed
that acute PD-L1 blockade minimally affected effector T-cell
priming and Th1/Tc1 differentiation as determined by the
in vitro ICS staining at day 5 post infection. However, as
determined by in vivo ICS, acute blockade of PD-L1 drastically
enhanced in vivo production of the inflammatory cytokines,
IFN-g, and TNF-a, which were previously shown to contribute
to host morbidity and tissue injury during RSV infection.47,48
These data suggest that the primary function of PD-L1 and
PD-1 interaction in the infected lungs in vivo is to limit
inflammatory activities of T cells in situ upon their arrival
at the site of infection (i.e. the lungs) and, thereby suppress the
development of excessive pulmonary inflammation and injury
during RSV infection. Notably in this regard, the blockade of
PD-L1 in vivo lead to enhanced accumulation of effector T cells
in the lung later during RSV infection (i.e. day 9), presumably
due to enhanced recruitment caused by enhanced chemokine
levels in the lung and/or elevated local proliferation/survival of
effector T cells in the lung. Furthermore, although we did not
directly examine Th2 and Th17 cytokine production by T cells
during RSV infection, we believe that the acute blockade of PD-
L1 did not alter the nature of inflammatory type, but rather
resulted in a much intensified inflammatory immune response
as evidenced by the increased levels of Th1, Th2, and Th17
associated cytokines present in the airway of mice that received
a-PD-L1.
We previously demonstrated that lung CD11cþ cells
(mainly inflammatory DCs) are required to stimulate the
in situ production of effector cytokines during influenza
infection.35 Similarly, we found that lung inflammatory DCs
rather than CD45 cells (primarily epithelial cells) potently
stimulated cytokine production by effector T cells during RSV
infection, in spite of the fact that RSV primarily infects
epithelial cells. Previous analyses have shown that differential
activities of effector T cells (i.e., cytokine production vs. killing
of target cells) are governed by the strength of stimulation they
received following interaction with target cells.35,49,50 The
engagement of co-stimulatory receptors (i.e., B7 molecules) on
effector CD8þ T cells by lung CD11cþ DCs provides the
additional signal strength necessary for the production of pro-
inflammatory cytokines by effector T cells, while lung epithelial
cells, which lack the expression of B7 molecules, deliver weak
stimulation signals to effector T cells adequate for the triggering
of the T-cell killing degranulation process but not effector
cytokine production.35,49 We showed here that lung CD11cþ
inflammatory DCs also express high levels of PD-L1 and thus
are capable of delivering negative signals to effector T cells
to limit their cytokine production. Thus, DCs possess
both positive and negative signals to modulate the in situ
inflammatory activities of tissue effector T cells and thereby
directly impact viral pathogenesis through modulation of
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effector T cells. Interestingly, as we reported previously
following IL-10 receptor blockade, the down-modulation of
the inflammatory activities of effector T cells does not
significantly alter the ability of effector T cells to aid in virus
clearance, suggesting that it is possible to uncouple inflam-
matory activities of effector T cells and their anti-viral activities
in vivo during RSV infection. Such strategies, achieved by either
selective blockade of co-stimulatory signaling in situ, such as
CD28 signaling, or by enhancing the activities of inhibitory
molecule activities (such as IL-10 and PD-L1, or Treg activities)
may serve as potential future therapeutics for acute respiratory
viral infections.
Both type I and II IFNs have been shown to induce PD-L1
expression on DCs in vitro. However, the relative contributions
of these cytokines in the in vivo expression of PD-L1 are less
clear. Through the blockade of the action of type I and/or type II
IFNs, we showed that type I and II IFNs co-operatively induced
the expression of PD-L1 in vivo. Interestingly, different strains of
RSV viruses have been shown to differentially regulate type I
and/or II IFN production in vivo,51 suggesting that theymay also
differentially regulate PD-L1 expression in vivo. Nevertheless,
our finding that PD-L1 blockade leads to enhanced IFN-g
production in vivo, suggesting that pro-inflammatory IFN-g
response of effector T cells in response to RSV infection is
regulated through a feedback loop mediated by the regulated
expression of PD-L1 on DCs. Mechanistically, both type I and II
IFNs induced IRF1 gene expression inDCs. IRF1 was previously
demonstrated to regulate PD-L1 expression on human tumor
cell lines.39 We found that ectopic expression of IRF1 induced
PD-L1 expression on DCs and the ablation of IRF1 in vivo
abrogated PD-L1 expression. Thus, these multiple lines of
evidence described here formally established that IRF1 is critical
for the expressionofPD-L1 onDCs in vivoduringRSV infection.
In summary, we showed that PD-1 is highly expressed on
effector T cells in the respiratory tract during both murine and
human RSV infection. We demonstrated that PD-L1–PD-1
interaction is critically important for restricting the inflam-
matory activities of effector T cells during RSV infection.
Furthermore, we identified that the IFN–STAT1–IRF1 mole-
cular axis in inflammatory DCs is critical for the physiological
regulation of PD-L1 and the in situ activities of effector T cells in
the lungs. Our findings may provide the groundwork for future
studies employing PD-1–PD-L1 pathway as a therapeutic
option in the treatment of severe RSV infection.
METHODS
Ethics statement. Patient sample collection was approved by Indiana
University (IU) Institutional Review Boards (IRB, IRB approval
number: 1212010151). Written informed consents were signed by
English-speaking parents or guardians. Animal study was carried out
in strict accordance with the AnimalWelfare Act (Public Law 91–579)
and the recommendations in the Guide for the Care and Use of
Laboratory Animals of theNational Institutes of Health (OLAW/NIH,
2002). The protocol was approved by the University of Virginia
Animal Care and Use Committee (UVA ACUC, Protocol Number:
2230) and the animal care and use program at Indiana University
School of Medicine (IUSM, Protocol number: 10006). Both
institutions are in compliance with all applicable federal regulations
and accredited by AAALAC. Daily care for the animals was provided
by the trained staff from Laboratory Animal Resource Center (LARC)
in UVA and IUSM.
RSV patients and healthy controls. A total of 10 RSV subjects and 4
healthy controls were selected for this study. Nasal washes from six
subjects contained sufficient numbers of cells and were analyzed and
compared with cells from peripheral blood mononuclear cells from
these subjects. We were unable to obtain enough cell numbers in nasal
washes for flow cytometry analysis in healthy patients and the other
RSV subjects. All RSV subjects and healthy controls were recruited
during the 2013 RSV season. The chosen RSV subjects were inpatients
at Riley Hospital for Children in Indianapolis, and confirmed to be
RSV positive by direct fluorescent antibody assay or PCR. Healthy
controls were included if no viral infection, fever, and usage of
antibiotic were detected. All selected RSV subjects and healthy controls
wereo3 years of age without diagnosis of chronic diseases, bleeding
disorder, history or current use of palivizumab, and inability to provide
blood sample; and have to be accompanied by English-speaking
parents or guardians.
Nasal wash procedure. The subject was placed on a continuous
oxygen monitor for this procedure. During the procedure, the subject
was held in the lateral recumbent position, and 5ml of sterile normal
saline solution was instilled into the upper nostril 1–2ml at a time over
a total time of 30–60 s. Nasal lavage fluid (NLF) passively flowing from
the inferior nostril was collected in a cup or specimen container. A soft
rubber bulb syringe was used to gently suction any remaining fluid
from both nostrils and added to the material in the cup. The NLF was
then transferred to a capped polypropylene tube, placed on crushed ice,
and then transported to the laboratory for initial processing within 2 h
of the lavage being completed.
Blood draw. Five milliliters (minimum of 3ml) of whole blood was
obtained by peripheral venipuncture. For the patient who already has a
central venous catheter in place, blood was drawn from the central
venous catheter preferentially. After the blood was drawn, the sample
was transferred immediately to the laboratory for initial processing.
Collection of cells from blood and NLF. Peripheral blood mono-
nuclear cells were isolated over Ficoll; for nasal wash samples, the fluid
was first filtered over a 70-mm cell strainer (BD Falcon, Bedford, MA),
and then centrifuged for 5min at 1,500 r.p.m. at 4 1C. Both the cell
pellets from blood and NLF were re-suspended in 20% fetal bovine
serum–RPMI (Gibco, Grand Island, NY) supplemented with 10%
dimethylsulfoxide, and immediately frozen for future staining.
Mice and infection. WT BALB/c and C57BL/6 mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). IL-10-enhanced-
green fluorescent protein reporter mice (Vert-X), Ifnar1 / ,
Stat1 / , and Irf1 / micewere bred in house. Allmicewere housed
in a specific pathogen-free environment and all animal experiments
were performed in accordance with protocols. The A2 strain of RSV
was grown in HEp-2 cells (ATCC, Manassas, VA) and tittered
for infectivity. Mice were infected at age of 8–10 week with a dose of
1–1.2 107 p.f.u. RSV in serum-free Iscove’s medium (Gibco)
intranasally following anesthesia with ketamine and xylazine.
Administration of Ab in vivo. Mouse PD-L1 (B7-H1) monoclonal
antibody (clone 10B5) was purified on a protein G column from the
supernatant of the hybridoma cell line (kindly provided by Dr Lieping
Chen from Yale University). Anti-PD-L2 blocking Ab (clone TY25)
was purchased from Bio-X-Cell (West Lebanon, NH). Control Abs
(hamster IgG and Rat IgG) were obtained from Jackson Immu-
noResearch Laboratories. The blocking Abs were injected IP with a
dose of 1.2mg per mouse at 4 d.p.i. and 600 mg per mouse at 6 d.p.i.,
respectively. Neutralizing IFN-g Ab (clone XMG1.2, Bio-X-Cell) was
injected IP at dose of 1mg per mouse.
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Evans-blue dye leakage measuring lung injury. Twenty-four hours
following the secondary anti-PD-L1 blockadeAb injection (7 days post
RSV infection), mice were injected via the tail vein with Evans-Blue
Dye (50mg kg 1). Thirty minutes following the injection, BAL was
performed by flushing the airway multiple times with a single volume
of 600ml sterile phosphate-buffered saline. BAL fluid was then spun
down and the supernatant was collected to measure the absorbance at
620 nm by spectrophotometer.
Histology. Twenty-four hours post the secondary anti-PD-L1 or
control IgG Ab injection on day 7 post infection, whole lungs of RSV-
infected mice were harvested and fixed in 10% buffered formalin
phosphate (Fisher Scientific, Fair Lawn, NJ). Fixed lungs were
embedded in paraffin, sectioned at 4-mm thickness, and stained by the
Indiana University Pathology Laboratory. Slides were then stained
with hematoxylin and eosin.
Airway cytokine determination. BAL fluid with a volume of 600 ml
was obtained and spun down as described.52 Supernatants were then
collected for multiplex analysis (Millipore, Billerica, MA) according to
the manufacturer’s instructions.
Ex vivo restimulation of pulmonary effector CD8þ T cells.
Pulmonary effector CD8þ T cells were purified from RSV-infected
lungs 8 d.p.i. using MACS-beads (Miltnenyi Biotec) and seeded into
round-bottom 96 wells (105 cells per well) in presence of plate-bound
a-CD3 Ab with various concentrations to trigger TCR engagement,
inducing robust inflammatory cytokine production by lung effector T
cells. Recombinant PD-L1–Ig fusion protein (R&D) was added at the
time of a-CD3Ab administration with a concentration of 10 mgml 1
to interact with PD-1 expressed at effector T cells. CD8þ T cells
cultured with medium alone with/without PD-L1–Ig were served as
controls. Supernatants were harvested 24 h after co-incubation and
enzyme-linked immunosorbent assay (ELISA) was performed to
measure the inflammatory cytokine IFN-g production.
In co-culture of CD8þ T cells with inflammatory DCs/epithelial
cells, effector CD8þ T cells were purified from RSV-infected lungs 8
d.p.i. and seeded into 96-well round-bottomwells with a concentration
of 5x104 cells per well. Inflammatory DCs and epithelial cells (CD45-)
were directly sorted fromRSV-infected lungs 5 d.p.i. and co-incubated
directlywithCD8þ T cells at various ratios.a-PD-L1was finally added
into the co-culture with a concentration of 20mgml 1 to block the
interaction between PD-L1 (expressed by inflammatory DCs/epithe-
lial cells) and PD-1 (expressed by CD8þ T cells). Twenty-four hours
later, supernatants were harvested tomeasure the production of IFN-g
by ELISA (Biolegend, San Diego, CA).
Quantitative reverse transcription PCR. RNA from the infected
lungs was isolated via Trizol (Invitrogen, Grand Island, NY) and
treated it with DNase I (Invitrogen). RNA from cultured cells was
isolated using RNA-extraction kit (Sigma, St Louis, MO). Random
primers (Invitrogen) and super-script II (Invitrogen) were used to
synthesize first-strand complementary DNAs from equivalent
amounts of RNA fromeach sample. Real-timeRT-PCRwas performed
in a 7000 Real-Time PCR System (Applied Biosystems, Grand Island,
NY) with SYBR Green PCR Master Mix (Applied Biosystems). Data
were generated by the comparative threshold cycle (DCT) method by
normalizing to hypoxanthine-guanine phosphoribosyltransferase.
The sequences of the primers are available upon request.
Plaque assaymeasuring RSV virus. Supernatant of BALF was serially
diluted with serum-free MEM (Cellgro, Manassas, VA) on ice, and then
were inoculated onto 90% confluent HEp-2 cells in six-well plate. After
90min of incubation at 37 1C, the inoculant was removed and sup-
plemented with 1:1 mix of complete 2 EMEM (Lonza, Walkersville,
MD) and 1% low meting point agarose (Promega, Madison, MA). Four
days later, theplatewas fixedwith 1% formalin-phosphate-buffered saline,
and stained with 0.05% neutral red (Fisher). The plaques were counted
and viral load was expressed as the number of p.f.u.ml 1 of BALF.
Tfh, germinal center B cells and RSV-specific IgG measurement.
Mediastinal lymph nodes cell suspensions of RSV-infected mice were
used for detection of Tfh and germinal center B cells. Tfh cells were
defined as CD4þPD-1þCXCR5þ cells, and germinal center
B cells were defined as B220þCD95þGL-7þ cells. For the detection of
RSV-specific IgG, we coated ELISA plates (Themo Scientific,
Rochester, NY) with diluted virus overnight at 4 1C. Following
blockade of non-specific binding, serially diluted serum and BALFwas
then incubated with coated RSV for 2 h at room temperature, and then
detected with secondary biotin-conjugated anti-mouse IgG
(eBioscience, San Diego, CA) followed by Avidin-horseradish per-
oxidase (Biolegend) and TMB substrate solution (Biolegend). The
absorbance was read at 450 nm by spectrophotometer.
Intracellular cytokine staining. Measurement of IL-10 and IFN-g
producing cells in vivo was based on a previously described proto-
col.16,53 Briefly, at indicated days post RSV infection, mice were
injected IV with 500 ml of a phosphate-buffered saline solution
containing 750 mg Monensin (Sigma) 6 h before harvesting. Lung
single cell suspensions were prepared in the presence of monensin.
Cells were then fixed and permeablized and intracellular
IL-10 and IFN-g staining as described.16,53 Lung single cell suspensions
were generated as described.53 Lung cells were subsequently re-stimu-
lated with PMA (100 ngml 1) and ionomycin (1mgml 1) in the
presence of Golgi-Stop (1 ml ml 1) for 4 h. Then cells were fixed
and permeablized using the Cyto-Fix and Perm-Wash system
(BD Biosciences). Cell surface CD8þ , and intracellular IL-10 and
IFN-g were stained accordingly.16,53
Generation ofmixedBM chimeras. WT mice were lethally irradiated
(1,100 rad) and IV injected with the 1:1 mixed BM cells from WT
(CD45.1þ ) mice and congenic BM cells from either IRF1- or STAT1-
deficient (CD45.2þ ) mice. After 12 weeks for reconstitution, the
chimeric mice were then infected with RSV A2 virus.
Construction of IRF1-expressing retrovirus. The full-length mouse
IRF1 was amplified by PCR from a plasmid containing the com-
plementary DNA of IRF1 (ATCC) using the primers: IRF1-F1 (50-GC
CACCATGCCAATCACTCGAATG-30) and IRF1-R1 (50-GTTGTTG
TCGACCTATGGTGCACAAGGAATGGCCT-30). Primer IRF1-F1
contains no enzyme restriction site, whereas primer IRF1-R1 contains
a restriction site for SalI. The PCR product was then digested with SalI,
gel purified, and ligated into the pre-linearized retroviral vector
backbone encoding a marker of Thy1.1 (MSCV-Thy1.1), which con-
tains a blunt end at 50 and a SalI site at 30. This ligation thus generated a
bicistronic retrovirus encoding both IRF1 and Thy1.1 (MSCV-IRF1-
Thy1.1). The fidelity of MSCV-IRF1-Thy1.1 was confirmed to be
identical to the sequence deposited in the gene bank.
Retroviral transduction of BMDCs. BMDCs were generated as
described and cultured in presence of granulocyte–macrophage
colony-stimulating factor (20ngml 1).54 At days 2 and 3 of culture,
cells were transduced with bicistronic retrovirus expressing Thy1.1
only (MSCV-Thy1.1, control), orMSCV-IRF1-Thy1.1 (IRF1) through
spin infection (2,500 r.p.m.; 2 h) in presence of polybrene
(10 mgml 1), 2-ME, andHepes.55Viral supernatant was replaced with
the former culture after transduction. On day 5, transduced BMDCs
(Thy1.1þ ) were analyzed by flow cytometry for PD-L1 expression.
Flow cytometry analysis. All fluorescence-activated cell sorting
(FACS) antibodies were purchased from Biolegend, BD Biosciences or
eBioscience. Cells were acquired through FACSCalibur, FACSCanto,
or LSR II apparatus (BD Biosciences). Data were then analyzed by
using FlowJo software (Treestar, Ashland, OR).
Statistical analyses. Data are reported as mean±s.e.m. Analysis
of variance, parametric (paired or unpaired Student’s t-test) or
nonparametric (Mann–Whitney test) t-tests were used, where noted.
P-values40.05 are considered not significant.
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